4-28-2020 SmallCapVoice Interview with Q BioMed (QBIO)

Q BioMed (OTCQB: QBIO) (“the Company”) CEO Denis Corin called in to SmallCapVoice.com to discuss the recent news and events for the Company. Very early on in the coronavirus saga, that would evolve into a global health pandemic, QBIO made a major announcement about the work being done its research partner Mannin Research Inc. The combined efforts of the two companies was to develop a potential adjunct treatment for various infectious diseases like the coronavirus. Recent news highlighted the urgency for the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. Corin gives an update as well as an overall overview of QBIO’s work in this area.

Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏. Please visit http://www.QBioMed.com and sign up for regular updates.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $875 from the company on 4-28-2020 for 30 days of Audio Interview service.

Link to full disclosure about compensation paid to SmallCapVoice.com by companies featured on our website or in our e-mail communications.